The inoculum effect of antibiotics against CTX-M-extended-spectrum β-lactamase-producing Escherichia coli

Annals of Clinical Microbiology and Antimicrobials

Volumn 13, Issue 1, 2014, Pages

  Wu, Na ^a   Chen, Bai Y ^a   Tian, Su F ^a   Chu, Yun Z ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Escherichia coli; Extended spectrum lactamases (ESBLs); Inoculum effect

Indexed keywords

CEFEPIME; CEFMINOX; CEFOTAXIME; CEFTAZIDIME; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; ANTIINFECTIVE AGENT; BETA LACTAM; BETA LACTAMASE;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BROTH DILUTION; CONTROLLED STUDY; CTX M EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ESCHERICHIA COLI; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ESCHERICHIA COLI; GENOTYPE; INOCULATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; BACTERIAL LOAD; DRUG EFFECTS; ENZYMOLOGY; ESCHERICHIA COLI; HUMAN; MICROBIAL SENSITIVITY TEST; SECRETION (PROCESS);

ANTI-BACTERIAL AGENTS; BACTERIAL LOAD; BETA-LACTAMASES; BETA-LACTAMS; ESCHERICHIA COLI; HUMANS; MICROBIAL SENSITIVITY TESTS;

EID: 84910087341     PISSN: None     EISSN: 14760711     Source Type: Journal    
DOI: 10.1186/s12941-014-0045-1     Document Type: Article

References (12)

1. Performance standards for antimicrobial susceptibility testing: twentieth information supplement. Document M100-S20 2010, CLSI, Wayne, PA.
2. Wang P, Hu F, Xiong Z, Ye X, Zhu D, Wang YF, Wang M. Susceptibility of extended-spectrum-β-lactamase-producing Enterobacteriaceae according to the new CLSI breakpoints. J Clin Microbiol 2011, 49:3127-3131. 10.1128/JCM.00222-11, 21752977.
3. Paterson DL, Ko WC, VonGottberg A, Casellas JM, Mulazimoglu L, Klugman KP, Bonomo RA, Rice LB, Mccormack JG, Yu VL. Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum beta-lactamase: implications for the clinical microbiology laboratory. J Clin Microbiol 2001, 39:2206-2212. 10.1128/JCM.39.6.2206-2212.2001, 11376058.
4. Kang CI, Kim SH, Park WB, Lee KD, Kim HB, Kim EC, Oh MD, Choe KW. Bloodstream infections due to extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy. Antimicrob Agents Chemother 2004, 48:4574-4581. 10.1128/AAC.48.12.4574-4581.2004, 15561828.
5. Queenan AM, Foleno B, Gownley C, Wira E, Bush K. Effect of inoculum and beta-lactamase activity in AmpC- and extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli and klebsiella pneumoniae clinical isolates tested by using NCCLS ESBL methodology. J Clin Microbiol 2004, 42:269-275. 10.1128/JCM.42.1.269-275.2004, 14715764.
6. Segatore B, Setacci D, Perilli M, Franchino L, Agnifili A, Rossolini GM, Amicosante G. Antimicrobial susceptibility of clinical isolates of Enterobacteriaceae producing complex beta-lactamase patterns including extended-spectrum enzymes. Int J Antimicrob Agent 2004, 23:480-486. 10.1016/j.ijantimicag.2003.10.011.
7. Rogers BA, Sidjabat HE, Paterson DL. Escherichia coli O25b-ST131: a pandemic, multiresistant, community-associated strain. J Antimicrob Chemother 2011, 66:1-14. 10.1093/jac/dkq415, 21081548.
8. Cantón R, Coque TM. The CTX-M beta-lactamase pandemic. Curr Opin Microbiol 2006, 9:466-475. 10.1016/j.mib.2006.08.011, 16942899.
9. Su Fei T, Bai Yi C, Yun Zhuo C, Shuang W. Prevalence of Rectal Carriage of Extended-Spectrum-β-lactamase-producing Escherichia coli Among Elderly People in a Community Setting in China. Can J Microbiol 2008, 54:781-785. 10.1139/W08-059.
10. Paterson DL. Recommendation for treatment of severe infections caused by Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs). Clin Microbiol Infect 2000, 6:460-463. 10.1046/j.1469-0691.2000.00107.x, 11168179.
11. Rodriguez-Bano J, Navarro MD, Romero L, Muniain MA, Cueto MD, Rios MJ, Hernandez JR, Pascual A. Bacteremia due to extended-spectrum ß-lactamase-producing Escherichia coli in the CTX-M era: a new clinical challenge. Clin Infect Dis 2006, 43:1407-1414. 10.1086/508877, 17083012.
12. Lopez-Cerero L, Picon E, Morillo C, Hernandez JR, Docobo F, Pachon J, Rodriguez-Bano J, Pascual A. Comparative assessment of inoculum effects on the antimicrobial activity of amoxycillin-clavulanate and piperacillin-tazobactam with extended-spectrum β-lactamase-producing and extended-spectrum β-lactamase-non-producing Escherichia coli isolates. Clin Microbiol Infect 2010, 16:132-136. 10.1111/j.1469-0691.2009.02893.x, 19614715.